Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MUCINEX DM vs AMMONIUM CHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Guaifenesin increases respiratory tract fluid secretion to reduce mucus viscosity; dextromethorphan acts on sigma-1 receptors and NMDA receptor antagonism to suppress cough reflex.
Ammonium chloride is an acidifying agent. It dissociates to ammonium and chloride ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which lower blood and urinary p H. It also increases chloride concentration, promoting excretion of bicarbonate and other bases.
Temporary relief of cough due to minor throat and bronchial irritation,Temporary relief of chest congestion and mucus buildup
Treatment of metabolic alkalosis,Urinary acidification to enhance excretion of weak bases in poisoning,Expectorant (off-label)
One tablet (guaifenesin 600 mg / dextromethorphan HBr 30 mg) orally every 12 hours, not to exceed 2 tablets in 24 hours.
For metabolic alkalosis: 1-2 g orally 3-4 times daily; or 1 g (as 2 mmol/kg) intravenously over 4-6 hours, repeat as needed based on blood gas analysis.
Guaifenesin: 1-3 hours. Dextromethorphan: 3-30 hours depending on CYP2D6 phenotype; extensive metabolizers 3-8 hours, poor metabolizers 15-30 hours.
Terminal elimination half-life is approximately 8-12 hours in normal renal function; prolonged in renal impairment (up to 30 hours) due to reliance on renal acid excretion.
Guaifenesin undergoes hepatic metabolism via oxidation and conjugation; dextromethorphan is metabolized by CYP2D6 to dextrorphan, an active metabolite.
Ammonium chloride is metabolized in the liver via the urea cycle, where ammonium is converted to urea, consuming bicarbonate and generating hydrogen ions.
Guaifenesin: renal (primarily as inactive metabolites, <1% unchanged). Dextromethorphan: renal (as unchanged drug and metabolites, including dextrorphan). Approximately 80% eliminated in urine as metabolites.
Renal: >99% as ammonium ion (NH4+) and chloride (Cl-), with acid excretion via conversion of NH4+ to urea in liver; minimal biliary/fecal.
Guaifenesin: approximately 30% to albumin. Dextromethorphan: approximately 50% to albumin and alpha-1-acid glycoprotein.
<10% bound to plasma proteins (primarily albumin).
Guaifenesin: 0.8-1.5 L/kg. Dextromethorphan: 5-10 L/kg (extensive tissue binding).
Approximately 0.3-0.5 L/kg, distributing mainly in extracellular fluid; minimal intracellular penetration.
Oral: Guaifenesin ~100% (tablet/syrup). Dextromethorphan ~11% (extensive first-pass metabolism; varies with CYP2D6 phenotype).
Oral: 70-80% (subject to first-pass hepatic conversion of NH4+ to urea); intravenous: 100%.
Cr Cl 30-50 m L/min: administer every 24 hours. Cr Cl <30 m L/min: not recommended. Hemodialysis: not recommended. Peritoneal dialysis: not recommended.
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-60 m L/min: reduce dose by 50% and monitor for acidosis. For GFR >60 m L/min: no adjustment necessary.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or extend interval to every 24 hours. Child-Pugh C: not recommended.
No specific Child-Pugh dose adjustments; use with caution in severe hepatic impairment due to risk of encephalopathy.
Children ≥12 years: same as adult. Children 6-11 years: guaifenesin 300 mg / dextromethorphan 15 mg orally every 12 hours, not to exceed 2 doses in 24 hours. Children <6 years: not recommended.
For metabolic alkalosis: 50-100 mg/kg orally every 6-8 hours, not to exceed 6 g/day. Intravenous: 2-3 mmol/kg over 4-6 hours, repeat based on blood p H.
Start at lower end of dosing range (e.g., one tablet every 24 hours) due to age-related renal and hepatic decline; monitor for CNS effects and constipation.
Start at low end of dosing range; monitor renal function and electrolytes closely due to age-related decline in GFR.
None
None.
Do not use for persistent/chronic cough, cough with excessive phlegm, or cough due to smoking/asthma/COPD/emphysema,Serotonin syndrome risk with MAOIs or other serotonergic drugs,Dextromethorphan abuse potential,Hypersensitivity reactions
May cause metabolic acidosis, hyperammonemia in hepatic impairment, and electrolyte disturbances. Use with caution in patients with renal or hepatic disease, pulmonary insufficiency, or cardiac edema.
Concomitant use with MAOIs or within 14 days of MAOI therapy,Hypersensitivity to any component
Severe hepatic or renal impairment, primary respiratory acidosis, and patients with uremia or high serum bicarbonate levels.
No significant food-drug interactions. However, alcohol may potentiate CNS effects (drowsiness/dizziness) and should be avoided.
Avoid excessive consumption of alkaline foods (e.g., dairy products, fruits) as they may counteract the acidifying effect. Maintain a consistent diet to avoid fluctuations in acid-base balance.
FDA Category C for guaifenesin and dextromethorphan. First trimester: limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: no known fetal risks at recommended doses. Avoid high doses of dextromethorphan due to potential serotonin reuptake inhibition and theoretical risk of fetal serotonin syndrome.
Ammonium chloride is not associated with major human teratogenicity. However, due to its potential to induce metabolic acidosis, high doses may pose theoretical fetal risks, including fetal acidosis and altered fetal p H homeostasis, particularly in the second and third trimesters. No specific trimester-specific risks are well-documented.
Guaifenesin: excreted into breast milk in small amounts; no known adverse effects in infants at maternal therapeutic doses. Dextromethorphan: likely excreted into breast milk in low concentrations; M/P ratio not established. Use caution; monitor infant for sedation, respiratory depression, or constipation.
Ammonium chloride is excreted into breast milk in small amounts. The M/P ratio is not well-established. At therapeutic doses, exposure to the nursing infant is likely low and not expected to cause adverse effects. Caution is advised with high doses due to potential for maternal acidosis and subsequent infant effects. Consider monitoring infant for signs of acidosis if maternal therapy is prolonged or high-dose.
No dose adjustment required for guaifenesin or dextromethorphan during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased renal clearance) are not clinically significant at standard doses. Use the lowest effective dose for the shortest duration.
Pregnancy increases plasma volume and renal clearance, which may reduce the effectiveness of ammonium chloride as an acidifying agent. Higher doses may be required to achieve therapeutic effect, but this must be balanced against the risk of acidosis. No standard dose-adjustment guidelines exist; dosing should be individualized based on maternal acid-base monitoring. Avoid excessive doses that could cause severe acidosis.
Mucinex DM combines guaifenesin (expectorant) and dextromethorphan (antitussive). Guaifenesin is best taken with adequate fluid intake to thin mucus. Dextromethorphan is contraindicated with MAOIs and in patients with serotonin syndrome risk. Avoid use in patients with chronic cough due to smoking, asthma, or COPD without physician guidance.
Ammonium chloride is used as a systemic acidifying agent to treat metabolic alkalosis. Monitor serum electrolytes and acid-base status closely during therapy. Avoid in severe hepatic or renal impairment. Use with caution in patients with respiratory acidosis.
Take with a full glass of water to help loosen phlegm.,Do not crush or chew extended-release tablets; swallow whole.,Avoid driving or operating machinery if drowsy or dizzy.,Do not use with other cough/cold medications containing dextromethorphan.,Stop use and consult doctor if cough persists >7 days or with fever, rash, or headache.
Take this medication exactly as prescribed. Do not exceed the recommended dose.,Notify your doctor if you experience nausea, vomiting, confusion, or rapid breathing.,Avoid taking with antacids or alkalinizing agents as they may reduce effectiveness.,Stay hydrated unless otherwise directed by your physician.,Inform your healthcare provider of all medications you are taking, especially diuretics or corticosteroids.
No interactions on record
"Ammonium chloride, an acidifying agent, reduces urinary pH, which increases the renal clearance of lisdexamfetamine and its active metabolite d-amphetamine. This accelerated elimination leads to decreased systemic exposure and potentially diminished therapeutic efficacy of lisdexamfetamine. Clinically, patients may experience reduced symptom control for ADHD or binge eating disorder, requiring dose adjustments or alternative therapies."
"Sufentanil, a potent opioid analgesic, may increase renal excretion of ammonium chloride by promoting diuresis through opioid-induced release of antidiuretic hormone (ADH) and subsequent water reabsorption, leading to dilutional acidosis and enhanced ammonium excretion. This interaction can result in reduced serum ammonium levels and decreased efficacy of ammonium chloride as an acidifying agent, potentially compromising its therapeutic effect in metabolic alkalosis or urinary tract infections. Clinical outcomes may include incomplete correction of metabolic alkalosis or reduced antimicrobial activity of ammonium chloride in the urine."
"Ammonium chloride acidifies the urine, which increases the renal excretion of amphetamine by favoring its ionized form in the tubular lumen, thereby reducing its reabsorption. This leads to a decreased serum concentration of amphetamine and potentially diminished therapeutic efficacy. Clinically, patients may experience reduced mood-elevating or stimulant effects, requiring dose adjustment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MUCINEX DM vs AMMONIUM CHLORIDE, answered by our medical review team.
MUCINEX DM is a Expectorant/Antitussive Combination that works by Guaifenesin increases respiratory tract fluid secretion to reduce mucus viscosity; dextromethorphan acts on sigma-1 receptors and NMDA receptor antagonism to suppress cough reflex.. AMMONIUM CHLORIDE is a Expectorant/Systemic Acidifier that works by Ammonium chloride is an acidifying agent. It dissociates to ammonium and chloride ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which lower blood and urinary p H. It also increases chloride concentration, promoting excretion of bicarbonate and other bases.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MUCINEX DM and AMMONIUM CHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MUCINEX DM is: One tablet (guaifenesin 600 mg / dextromethorphan HBr 30 mg) orally every 12 hours, not to exceed 2 tablets in 24 hours.. The standard adult dose of AMMONIUM CHLORIDE is: For metabolic alkalosis: 1-2 g orally 3-4 times daily; or 1 g (as 2 mmol/kg) intravenously over 4-6 hours, repeat as needed based on blood gas analysis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MUCINEX DM and AMMONIUM CHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MUCINEX DM is classified as Category C. FDA Category C for guaifenesin and dextromethorphan. First trimester: limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and. AMMONIUM CHLORIDE is classified as Category C. Ammonium chloride is not associated with major human teratogenicity. However, due to its potential to induce metabolic acidosis, high doses may pose theoretical fetal risks, includ. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.